Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)

Phase III Clinical Trial

A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer
Trial Number: 06564844
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations